Pila Pharma AB
Research Pila Pharma AB (PILA) on Bullrun: market cap SEK 85.88M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPILA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 85.88M
- Financial periodFY2025
- RevenueSEK 1.13M
- Revenue growth45.4%
- Net income-SEK 17.00M
- Free cash flow-SEK 6.63M
Valuation Snapshot
latest market cap is SEK 85.88M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 1.13M | -SEK 17.00M | -SEK 6.63M | n/a | n/a | SEK 15.90M | n/a | SEK 14.65M |
| FY2024 | SEK 774.89K | -SEK 11.24M | -SEK 7.82M | n/a | -0.44 | SEK 4.89M | n/a | SEK 5.26M |
| FY2023 | SEK 1.46M | -SEK 9.93M | -SEK 4.85M | 100.0% | -0.42 | SEK 5.95M | n/a | SEK 6.66M |
| FY2022 | SEK 1.88M | -SEK 26.78M | -SEK 9.09M | 100.0% | -1.38 | SEK 7.24M | SEK 0 | SEK 9.53M |
| FY2021 | n/a | n/a | n/a | n/a | -1.18 | n/a | SEK 0 | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | SEK 85.88M | n/a | n/a | n/a |
About Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pila Pharma AB's market cap?
Pila Pharma AB's market capitalization is SEK 85.88M.
What does Pila Pharma AB do?
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.